1
项与 AT-I9 (Ucello Therapeutics) 相关的临床试验Safety and Efficacy of Universal Chimeric Antigen Receptor-modified AT19 Cells in Patients With CD19+ Relapsed/Refractory Hematological Malignancies: a Single-center, Open-label, Single-arm Clinical Study
This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of universal chimeric antigen receptor-modified AT19 cells in patients with relapsed or refractory hematological malignancies.
100 项与 AT-I9 (Ucello Therapeutics) 相关的临床结果
100 项与 AT-I9 (Ucello Therapeutics) 相关的转化医学
100 项与 AT-I9 (Ucello Therapeutics) 相关的专利(医药)
100 项与 AT-I9 (Ucello Therapeutics) 相关的药物交易